Valrox

Valrox (valoctocogene roxaparvovec) is a gene therapy designed to treat hemophilia A, a condition where blood doesn’t clot properly due to low levels of factor VIII. It introduces a working copy of the factor VIII gene into a patient’s liver cells, allowing the body to produce its own clotting factor naturally. Delivered via a single infusion, Valrox aims to reduce or eliminate the need for frequent factor VIII injections, improving quality of life. It represents a significant advance in potentially providing long-lasting treatment for hemophilia A by addressing the disease at its genetic root.